Evidence map›Paper›PMID 36348431›Full record

ArticleAntimicrobial resistance and infection control2022

High prevalence of resistance to third-generation cephalosporins detected among clinical isolates from sentinel healthcare facilities in Lagos, Nigeria.

Emelda E Chukwu, Oluwatoyin B Awoderu, Christian A Enwuru, Ebelechukwu E Afocha, Rahman G Lawal, Rahaman A Ahmed, Ishola Olanrewaju, Chika K Onwuamah, Rosemary A Audu, Folasade T Ogunsola

Open access · goldAbstract read
In one paragraph

Article in Antimicrobial resistance and infection control, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. City or Suburb, Resistance Flows: Wastewater-BorneAntibiotics (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Emelda E ChukwuAntimicrobial Resistance Research group, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria. emeldachukwu123@gmail.com.
Oluwatoyin B AwoderuAntimicrobial Resistance Research group, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Christian A EnwuruAntimicrobial Resistance Research group, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Ebelechukwu E AfochaAntimicrobial Resistance Research group, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Rahman G LawalAntimicrobial Resistance Research group, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Rahaman A AhmedCenter for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Ishola OlanrewajuAntimicrobial Resistance Research group, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Chika K OnwuamahCenter for Human Virology and Genomics, Microbiology Department, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Rosemary A AuduAntimicrobial Resistance Research group, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Folasade T OgunsolaAntimicrobial Resistance Research group, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Nigerian Institute of Medical Research · NGUniversity of Lagos · NG

Funding

Nigeria HIV Research Training ProgramD43TW010934 · FIC · EMORY UNIVERSITY · PI Ighovwerha Ofotokun · 2019 to 2026
$2.4M
FIC NIH HHS D43 TW010934
6 · The paper itself

Abstract

backgroundAntimicrobial resistance (AMR) in bacterial pathogens is a worldwide concern that demands immediate attention. Most information on AMR originates from high-income countries and little is known about the burden in Africa, particularly Nigeria. Using four sentinel sites (General hospitals) in Lagos State, this study sought to estimate the burden of AMR.

methodsThis is a hospital-based surveillance using secondary health care centres. Four sites were randomly selected and included in the study. Clinical isolates were collected over a period of 6 months for each site from August 2020 to March 2021. All isolates were characterised and analysed for resistance to 15 antibiotics using the Kirby-Baur method. Multiplex PCR assay was used for the detection of Extended spectrum beta lactamase genes. Data analysis was done using SPSS version 27.0.

resultsFour hundred and ninety-nine (499) patients consented and participated in this study, consisting of 412 (82.6%) females and 87 (17.4%) males. The mean age ± SD of the participants was 33.9 ± 13.8 with a range of 1-89 years. The majority (90.8%) of the participants were outpatients. Two hundred and thirty-two (232) isolates were obtained from 219 samples, comprising of 120 (51.7%) Gram positive and 112 (48.3%) Gram negative organisms. Key bacterial pathogens isolated from this study included Staphylococcus aureus (22.8%), Escherichia coli (16.4%), Staphylococcus spp. (15.9%), Enterococcus spp. (7.3%) and Klebsiella pneumoniae (6.5%). There was high prevalence of multi-drug resistance (79.3%) among the isolates with 73.6% of Staphylococcus aureus phenotypically resistant to methicillin and 70% possessed the MecA gene. 76.5% of Enterococcus spp. isolated were Vancomycin resistant. Overall, resistance to Cephalosporins was most frequently/commonly observed (Cefotaxime 87.5%).

conclusionA high incidence of AMR was identified in clinical bacteria isolates from selected general hospitals in Lagos State, highlighting the necessity for the implementation of national action plans to limit the prevalence of AMR. Surveillance via collection of isolates has a lot of promise, especially in resource-limited environments.

Indexed as

CefotaximeStaphylococcal InfectionsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolDelivery of Health CareEnterococcusEscherichia coliFemaleHumansInfantMaleMicrobial Sensitivity TestsCefotaximeAntibioticsAntimicrobial resistanceClinical isolatesESBL genesMecANigeriaResistance genesStaphylococcus aureus

Identifiers

PMID36348431
PMCPMC9640893
OpenAlexW4308591131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.